20% Human Albumin Solution Fluid Bolus Administration Therapy in Patients after Cardiac Surgery-II

Phase 2

Completed

• Conditions: Cardiac Surgery; Critical illness; Anaesthesiology - Anaesthetics; Surgery - Other surgery; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12620000137998
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-02-12
• Study Completion: 2022-09-05
• Last Update Posted: 8 July 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 480

Inclusion Criteria

The treating clinician wishes to administer fluid bolus therapy (FBT) after cardiac surgery.

Exclusion Criteria

Age less than 18 years
Pregnancy
Patients who have previously received a FBT prescribed in the ICU after cardiac surgery (NB patients who have received FBT in the ICU prior to surgery remain eligible).
Contraindication to study fluid e.g. patients with known or suspected allergy to albumin or crystalloid fluid
Documented refusal of any study fluid (i.e. a patient may refuse to receive Human Albumin Solution which is in 20% and 4% albumin)
Death is deemed to be imminent or inevitable during this admission, and either the attending physician, patient or substitute decision-maker is not committed to active treatment
Off pump cardiac surgery
Patient who have previously been enrolled in this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration of vasopressor therapy (in hours) censored at day 7. Defined by discontinuation of all vasopressors for at least 4 consecutive hours in the presence of a MAP>65mmHg or target MAP set by the clinician in charge of the patient’s care for the same 24-hour period.[ at day 7]